Revenue Analysis - NVAX
Comprehensive quarterly and annual revenue breakdown by product lines and geographic regions to identify growth drivers and market opportunities.
NVAX Corporation
Annual
Revenue by Product Line
Latest quarterly revenue breakdown by product segments
Quarterly Product Revenue
Product Revenue Details
Detailed breakdown of revenue by product line
Licensing, Royalties, and Other
0.0% of total revenue
$97.3M
Product
0.0% of total revenue
$42.2M
Supply Sales
0.0% of total revenue
$32.6M
Nuvaxovid Sales
0.0% of total revenue
$9.6M
Historical Revenue Data
Quarterly product revenue breakdown over time (Last 6 records)
| Date | Licensing, Royalties, and Other | Nuvaxovid Sales | Product | Supply Sales |
|---|---|---|---|---|
| 3/31/2026 | $97.3M | $9.6M | $42.2M | $32.6M |
| 12/31/2025 | $0 | $19.6M | $660.9M | $19.6M |
| 9/30/2025 | $57.0M | $-332000 | $13.4M | $13.8M |
| 6/30/2025 | $228.5M | $-2093000 | $10.7M | $12.8M |
| 3/31/2025 | $45.0M | $608.0M | $621.7M | $13.7M |
| 12/31/2024 | $50.1M | $0 | $49.8M | $0 |
Revenue Trend Analysis
Analysis of major growing and declining segments based on recent revenue data
Product Segments
Growing Segments
Supply Sales+66.4%
Declining Segments
Product-93.6%
Nuvaxovid Sales-51.2%
Geographic Regions
Growing Regions
Europe+497.4%
Declining Regions
Rest of the World-28.9%
UNITED STATES-13.6%
Earnings Reports
Want to see how NVAX's earnings relate to revenue? View quarterly earnings results, EPS history, and earnings surprises to understand the company's profitability.
View Earnings Reports